Argireline

What Argireline does

Argireline is acetyl hexapeptide-8, a cosmetic peptide used in wrinkle serums and creams. Some small trials found smoother lines; others found no added benefit. A “10% Argireline” formula can contain a diluted ingredient solution, so it does not mean 10% pure peptide. Irritation can occur, and topical evidence does not establish injection safety.

• In a small trial on eye-area wrinkles, more people improved with it than with a placebo cream. (Studied in a trial)
• In a trial, a dissolving microneedle patch with it improved one eye-wrinkle measure more than a plain patch. (Studied in a trial)
• Some small studies found smoother lines, though others found no added benefit. (Studied in a trial)
• Some users report smoother frown lines with daily use; another reported no real change. (Reported by users)

Uses in the sources

• Studied for the appearance of eye-area wrinkles; results differ across formulas. (Studied in a trial) (source)
• Studied for oily skin; the small human trial did not show a significant benefit. (Studied in a trial) (source)
• Studied for eyelid spasms; small studies did not establish reliable symptom benefit. (Studied in a trial) (source)

Argireline dosage

Typical reported dose: Serum sold as 10% Argireline, twice daily on facial lines

• Early 10% emulsion: Reported 10% Argireline oil-in-water emulsion; amount per use not stated. twice daily, on the skin. Studied in a trial. Studied in: Healthy adult women. (source)
• Dry-skin cream: Fixed amount over the face; peptide strength and application mass not stated. every 12 hours, on the skin. Studied in a trial. Studied in: Women aged 40–57 with dry skin. (source)
• Oily-skin gel: Fixed amount over the face; peptide strength and application mass not stated. every 12 hours, on the skin. Studied in a trial. Studied in: Women aged 40–57 with oily skin. (source)
• Four-week eye-area trial: Argireline to the eye-area wrinkles; application amount not reported. twice daily, on the skin. Studied in a trial. Studied in: Chinese adults with peri-orbital wrinkles. (source)
• 0.005% eyelid study: 0.005% actual AH8 cream to eyelids; application mass not stated. twice daily, on the skin. Studied in a trial. Studied in: Adults with blepharospasm receiving toxin injections. (source)
• 0.025% eyelid study: 0.025% actual AH8 topical preparation; amount per use not reported. twice daily, on the skin. Studied in a trial. Studied in: Adults with primary blepharospasm. (source)

These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.

Work out syringe units with the dosing calculator

How to store Argireline

Comes as: Finished topical serum, Cream or gel, Research microneedle patch; distinct from ordinary topical use.

Mixed with: No established home reconstitution diluent, vial size or water volume. Cosmetic formulas are not sterile injection preparations..

• Finished serums and creams were tested as formulas; adding water changes their strength and preservation.
• Do not derive an injection recipe from topical ingredient percentages.

Before mixing: No validated universal raw-powder storage schedule or human injection preparation found.

After mixing: Follow the finished product’s stated storage and period after opening; protect from heat and keep the container clean.

Argireline side effects and risks

Reported side effects

• Stinging or burning: AH8 cream: stinging 2/7 (29%), burning 1/7 (14%); placebo burning 2/7 (29%)., mild. Stop if persistent; check the whole formula for irritants. (source)
• Itchy or dry skin: AH8 cream: itch 1/7 (14%), dryness 1/7 (14%); placebo itch 2/7, dryness 1/7., mild. Pause the product and seek advice if the rash continues. (source)
• Eyelid irritation: In the 0.005% spasm pilot: 2/12 active and 2/12 placebo (16.7% each)., mild. Stop eye-area use if irritation develops. (source)
• Contact dermatitis from a combination routine: 1/16 stopped the 2026 multi product/toxin study after eyelid misapplication. AH8 causality is unknown., moderate. Stop the product; seek assessment for a lasting rash. (source)
• Serious infection after injection: One published M. abscessus case; no rate can be calculated. This was facial injection, not topical use., serious. Prompt specialist assessment for persistent nodules or abscesses. (source)

Stop and get help if

• Trouble breathing, faintness, or face/throat swelling after a product: Stop use and seek emergency care now.
• Persistent or spreading facial nodules, pus or abscesses after an injection: Seek prompt medical care; report the injection and possible unusual infection.
• Eye pain, marked swelling or a new vision problem after eye-area use: Stop the product and seek urgent eye assessment.

Who should avoid it

• pregnant: No pregnancy safety data established. Pregnant people were excluded from cosmetic trials; This is a precaution.
• breastfeeding: No breastfeeding safety data established; nursing people were excluded from trials. This is a precaution.
• tryingToConceive: People trying to conceive were excluded from the crow’s-feet trial. This is a precaution; harm has not been demonstrated.
• under18: No pediatric cosmetic safety or dosing evidence located.
• other: Avoid a formula that previously caused an allergic reaction. Preservatives and fragrances can also be responsible.
• other: Cosmetic creams and powders are not established injection products. A serious facial injection infection is published.
• other: Damaged-skin absorption and irritation are not established. Relevant skin disease was excluded from cosmetic trials.
• other: CIR found insufficient cosmetic safety data above 0.005% actual peptide. A diluted ingredient percentage is a different measure.
• testedAthlete: Not named in the 2026 List; S0 may matter for unapproved pharmacological use. Obtain a product- and route-specific ruling.

Interactions

• Botulinum toxin products: Small add-on studies exist, but a reliable extra effect or interaction risk is unproven. Tell the injector about the whole routine.
• Other wrinkle peptides and multi-active skin routines: Extra benefit and interaction rates are unknown. Clinical inference: more products make the cause of irritation harder to identify.

Product quality risks

• Actual peptide content may differ from the front-label ingredient-solution percentage.
• An FDA research report screened 77 cosmetics and reported only 33% had detectable AH8 despite claims; sampling details were limited.
• Published mass-spectrometry work examined ingredient identity and oxidation products.
• Bacterial contamination can affect cosmetics; an AH8 facial-injection case caused persistent abscesses.

What to expect

A small wrinkle trial applied topical Argireline twice daily for four weeks before assessing results.

26 primary human records located, including cases and three registries without results. Small trials and mixed formulas limit confidence.

Key studies

• First wrinkle study: An early pilot found smoother wrinkles; its size limits confidence. (source)
• Cream versus gel: Both moisturizing formulas improved measurements without a placebo comparison. (source)
• Four-week wrinkle trial: A small trial found more responders than placebo. (source)
• Eyelid-spasm add-on pilot: The add-on pilot did not establish longer toxin benefit. (source)
• Higher-dose eyelid study: The tiny terminated study did not show useful symptom improvement. (source)
• Skin hydration and mechanics: The peptide changed one skin-mechanics measure; the base also moisturized. (source)

Argireline FAQ

• Is Argireline FDA-approved? No. Cosmetic ingredient, not an FDA-approved AH8 drug. Cosmetic sale is not drug approval. No approved therapeutic indication or drug dosing label located.
• How do people take it? On the skin, twice daily. Source: reported by users, not an established dose.
• What's the difference between Argireline and GHK-Cu? Argireline: a topical cosmetic peptide with small, mixed wrinkle studies and limited skin penetration. GHK-Cu: a copper-binding skin peptide with small topical studies and untested systemic injections. Why people pair them: reported in broader skin routines; no controlled study of this reported combination was located.
• Can I take it with Copper peptides? Reported in broader skin routines; no controlled study of this reported combination was located. Added benefit and combined-product stability are unknown. Source: reported by users. Ask a doctor before combining anything.
• Is it banned in sport? It is unclear (WADA 2026). The List does not name AH8. S0 covers unapproved pharmacological substances; absence by name does not establish permission for every route.
• How do I store it once opened? Follow the finished product’s stated storage and period after opening; protect from heat and keep the container clean.